What distinguishes Section 361 tissue allografts from Section 351 biological products?

Section 361 HCT/Ps are minimally manipulated, intended for homologous use, and regulated primarily to prevent communicable disease transmission without requiring premarket approval. Section 351 products involve more than minimal manipulation or non-homologous use, requiring full FDA premarket approval, investigational new drug (IND) applications, and biological license applications (BLA).

What temperature monitoring equipment is required for in-office tissue storage?

Practices must use calibrated, NIST-traceable digital data loggers capable of continuous temperature recording. Medical-grade refrigeration units with built-in high/low temperature alarms and secondary battery or generator backups are strongly recommended over consumer-grade units.

How long must tissue storage logs and donor eligibility records be retained?

Under 21 CFR Part 1271, practices must retain all records related to HCT/P receiving, storage, donor eligibility, and patient administration for at least 10 years after the date of administration or disposition, unless state regulations require a longer retention period.

What steps should a practice take if a storage unit experiences a temperature excursion?

The practice must immediately isolate and tag affected tissues as 'Quarantined - Do Not Use.' The practice manager should contact the tissue manufacturer with the temperature data log to determine if product stability was compromised before using or discarding the tissue.

Are medical practices required to register with the FDA as tissue establishments?

Practices that only receive, store, and administer Section 361 HCT/Ps solely for context within their own facility typically fall under professional practice exemptions and do not need to register as a tissue establishment. However, if a practice redistributes tissue to other offices or alters the tissue, FDA registration is mandatory.

FDA Section 361 Tissue Allograft Storage Guide

Under FDA Section 361 regulations (21 CFR Part 1271), medical practices storing human cells, tissues, and cellular and tissue-based products (HCT/Ps) must maintain continuous cold-chain verification, rigorous temperature logging, and absolute lot-to-patient traceability. Compliance requires adhering strictly to manufacturer-defined storage thresholds—ranging from controlled ambient to cryogenic temperatures—while establishing documented receiving, quarantine, and disposition protocols. Practices must maintain audit-ready records to demonstrate that stored tissue allografts remain safe, sterile, and free from risk of communicable disease transmission.

Understanding FDA 21 CFR 1271 and Section 361 HCT/Ps

The Food and Drug Administration regulates human cells, tissues, and cellular and tissue-based products under 21 CFR Part 1271. Products categorized under Section 361 of the Public Health Service Act are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. To qualify as a Section 361 HCT/P, a tissue allograft—such as amniotic tissue, umbilical cord morphometric matrix, or desiccated bone graft—must be minimally manipulated, intended for homologous use, and not combined with another drug or device component beyond standard systemic preservers.

While Section 361 products do not require premarket approval (unlike Section 351 biologics), practices using and storing them share regulatory responsibility for maintaining tissue integrity. When an tissue allograft arrives at a clinical facility, the practice becomes an extension of the tissue chain of custody. Failing to comply with appropriate receiving, handling, and storage guidelines can compromise biological functionality, expose patients to safety risks, and trigger regulatory sanctions during routine or targeted audits.

Critical In-Office Storage and Temperature Requirements

Storage compliance centers entirely on maintaining the precise environment designated by the tissue processor. Different forms of biologics require distinct thermal parameters:

Cryogenic Storage (-135°C or colder): Used primarily for viable cellular allografts. Requires specialized liquid nitrogen phase storage freezers equipped with continuous monitoring.
Ultralow Frozen Storage (-40°C to -80°C): Required for structural extracellular matrix allografts and liquid allografts preserved without cryogenic protectants.
Standard Frozen Storage (-20°C to -40°C): Applicable for select short-term structural tissues.
Refrigerated Storage (2°C to 8°C): Common for liquid amniotic flowables designed for near-term clinical use.
Controlled Room Temperature (20°C to 25°C): Reserved for dehydrated, desiccated, or lyophylized allograft membranes.

Practices must utilize dedicated, medical-grade cold storage units. Household units are non-compliant due to inconsistent internal airflow, auto-defrost temperature spikes, and inadequate temperature recovery following door openings.

In-Office Tissue Allograft Storage Checklist

To ensure operational compliance under 21 CFR 1271 Subpart D (Current Good Tissue Practice), practice administrators should implement the following structural workflow:

Receiving and Inspection: Immediately inspect outer shipping containers for damage, verify chemical indicator cards, and document the internal transit temperature upon arrival.
Quarantine Protocol: Isolate newly arrived tissue in a designated, labeled quarantine area within the storage unit until package integrity and donor eligibility documentation are verified.
Continuous Temperature Monitoring: Equip storage units with calibrated, NIST-traceable digital data loggers that record ambient temperature at minimum 15-minute intervals.
Visual Alarm Systems: Deploy physical and remote audible/visual alarms configured to alert key personnel immediately if temperatures drift outside established limits.
Secondary Power Backup: Connect medical freezers to dedicated uninterruptible power supply (UPS) systems or emergency generator circuits to protect inventory during facility outages.
Traceability and Inventory Logs: Log product description, tissue identification code (TIC), unique lot number, expiration date, donor eligibility status, receiving date, and internal assignment.
Quarantine for Excursions: Establish an immediate quarantine protocol for any tissue exposed to potential temperature deviations until written authorization for use is provided by the tissue processor.

Clinical Administration and Handling Standards

While practice administrators oversee procurement and environmental controls, treating physicians in specialized disciplines—such as pain management doctors and orthopedic specialists—must adhere to strict clinical handling protocols at the point of care.

A tissue allograft must remain in its original sterile packaging within the monitored storage environment until immediately prior to the procedure. Clinicians must confirm that the tissue donor eligibility certificate is present in the patient chart before opening the sterile barrier. Thawing procedures for frozen or cryopreserved tissue must strictly follow the manufacturer’s Instructions for Use (IFU). Forced thawing at improper temperatures or using unvalidated warm baths can denature extracellular proteins and destroy cellular viability.

Furthermore, once a package seal is broken, the product must be reconstituted (if applicable) and administered within the timeframe established by the manufacturer. Any unused portion of a single-use tissue allograft must be documented as wasted and discarded per biological waste guidelines; single-dose tissue containers can never be stored for subsequent patient application.

Vendor Auditing and Procurement Oversight

In-office storage compliance relies heavily on vendor selection. Practice managers must ensure that every tissue distributor and manufacturing partner operates under strict compliance standards. FDA registration of the tissue processor is mandatory, but robust vendor qualification goes further.

When evaluating tissue suppliers, request proof of current FDA Establishment Registration (Form FDA 3356), American Association of Tissue Banks (AATB) accreditation, and sample copies of Donor Eligibility Certificates. Responsible distributors provide comprehensive validation data regarding their cold-chain shipping procedures, clear thermal failure protocols, and responsive technical support. For detailed information on industry requirements, reviewing our clinical FAQ resource offers clarity on common operational challenges.

What This Means for Your Practice: Operational Next Steps

Maintaining FDA Section 361 compliance for in-office tissue storage protects patient health, preserves clinical efficacy, and safeguards practice business operations. Practice managers should immediately execute the following administrative actions:

Conduct a Storage Audit: Inspect current cold-storage equipment to ensure units are medical-grade, calibrated, and attached to continuous data loggers with secondary backup power.
Standardize Standard Operating Procedures (SOPs): Draft or update written SOPs covering allograft receiving, quarantine, temperature tracking, excursion response, and disposal.
Review Logs and Traceability: Confirm that every administered tissue allograft can be traced from the vendor invoice and donor lot number directly to the specific patient medical record.
Audit Vendors: Re-evaluate current tissue suppliers to ensure all documentation—including donor eligibility guidelines and thermal handling instructions—is up to date.

Partner with Dallas Regenerative Solutions

Navigating regulatory expectations while maintaining seamless clinical workflows requires reliable vendor partnerships. As an established distributor, Dallas Regenerative Solutions supplies compliant biologics, state-of-the-art medical devices, and operational guidance tailored to modern practices. Learn more about our background on our about page, or contact our clinical integration team today to discuss your practice's procurement and compliance needs.